Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MaxCyte, Inc. - Common Stock (NQ:MXCT)

0.7950 +0.0036 (+0.45%)
Streaming Delayed Price Updated: 12:01 PM EST, Feb 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MaxCyte, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs
TG Therapeutics to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support the development and commercialization of azer-cel, its allogeneic CD19 CAR T cell therapy program, for... 
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference
From MaxCyte, Inc
Via GlobeNewswire
News headline image
Glancy Prongay & Murray LLP Announces Investigation of MaxCyte, Inc. (MXCT)
From Glancy Prongay & Murray LLP
Via Business Wire
News headline image
MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MarketBeat Week in Review – 01/20 - 01/24
Stocks surged higher as investors reacted positively to dovish tariff news; next week will be highlighted by the Federal Reserve meeting and some tech earnings 
Via MarketBeat
Topics Economy Government World Trade
News headline image
MaxCyte: Building the Future of Cell and Gene Therapy Innovation
MaxCyte's proprietary Flow Electroporation technology enables companies like Vertex and CRISPR Therapeutics to get FDA approved for their gene-editing therapy. 
Via MarketBeat
News headline image
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Announces Retirement of Board Member Art Mandell
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics
Since 1999, MaxCyte’s non-viral cell engineering innovations have helped launch pioneering cell and gene therapy projects 
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte to Participate in Two Upcoming Investor Conferences
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Appoints Cynthia Collins to its Board of Directors
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases
Kamau to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support its homology-directed repair (HDR) novel gene correction technology 
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing Conference
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MXCT Stock Earnings: MaxCyte Beats EPS, Beats Revenue for Q2 2024 ↗
MXCT stock results show that MaxCyte beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development
Legend Biotech obtains license to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support its non-viral engineered pipeline portfolio across a variety of cell types including T... 
From MaxCyte, Inc
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Louisiana-Pacific Posts Upbeat Results, Joins Cricut, Elanco Animal, American Public Education And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
Why Upstart Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
 
Via Benzinga
News headline image
MXCT Stock Earnings: MaxCyte Beats EPS, Beats Revenue for Q1 2024 ↗
MXCT stock results show that MaxCyte beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)
Be Biopharma to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform within its Engineered B Cell Medicines programs 
From MaxCyte, Inc
Via GlobeNewswire
News headline image
Why Taysha Gene Therapies Shares Are Trading Higher By Around 27%; Here Are 20 Stocks Moving Premarket ↗
Shares of Taysha Gene Therapies, Inc. (NASDAQ: TSHA) rose sharply in today’s pre-market trading after the company reported a year-over-year increase in FY23 EPS results. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.